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This tutorial promotes good practice for exploring the rationale of systems18
pharmacology models. A safety systems engineering inspired notation ap-19
proach provides much needed rigour and transparency in development and20
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application of models for therapeutic discovery and design of intervention21
strategies. Structured arguments over a models development, underpinning22
biological knowledge, and analyses of model behaviours, are constructed to23
determine the confidence that a model is fit for the purpose for which it will24
be applied.25
Introduction26
When constructing a quantitative systems pharmacology (QSP) model there are many27
issues to consider, from what aspects of the biological system needs to be modelled, hence28
defining the scope of the model, to what modelling approach to use, through to how the29
model is developed, and what abstractions are to be made during the model development30
process. Likewise, there may be existing models that have been developed and are in31
use as part of an experimental study, but which may be seen as a blackbox where the32
rationale for their construction, use, and analysis is undocumented or was never coherently33
established.34
During model development various decisions have to be made, such as the inclusion of35
simplifications and assumptions in place of biological knowledge, which may be very rea-36
sonable but often are forgotten about or poorly documented. Yet these decisions impact37
the relationship between any predictions that model generates and the real biological38
system the model is aiming to capture, in turn impacting the level of confidence a re-39
searcher has in applying those predictions within their own studies. Work in Alden et al40
[4] presented a tool, Artoo, that permits the application of an adapted version of Goal41
Structuring Notation (GSN) [30] through which a structured argument is developed to42
show that a model is fit for the purpose for which it has been conceived. Within the43
context of modelling, an argument is constructed by making claims concerning aspects of44
model development, which are, where possible, supported by available evidence. In their45
description, Alden et al provide an overview of using argumentation to examine fitness46
for purpose, exemplifying application of the approach to explore the rationale underlying47
the development of a previously published simulation of secondary lymphoid organ devel-48
opment [7]. Thus Artoo was presented in a manner where claims were developed about a49
specific model, rather than focusing on the process by which claims could be developed50
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and how different types of evidence can be used to establish those claims. Of critical51
importance to that process, from which everything else flows, are two simple questions:52
1) Has the right model been developed to address the specific question of interest? and53
2) has the model been built correctly to address the specific question?54
On the surface these might sound like obvious questions to ask and people might be55
convinced that they have indeed satisfied both questions in a positive manner. However,56
what is the evidence for such an assertion? If the model developer was asked to provide57
clear evidence that their model is indeed fit for purpose, what evidence would be presented,58
and how would that evidence be presented? Consider a number of issues associated with59
model development: 1- what is the scope of your model in terms of the pharmacological60
question you intend to ask? 2- who, or what, have you relied on for the underlying evidence61
to build the model? 3 what assumptions did you make with respect to the biological62
system you are working on and how it works? 4 what assumptions did you make when63
moving from understanding your biological system, into mathematics? 5- why did you64
choose a particular modelling style over another; and there are potentially many more65
questions that could be asked. Indeed, alongside prompting these questions, adopting66
such an approach can support inter-team working, having to explain, and document,67
the rationale behind model development can promote greater transparency in the model68
itself, and open it to wider scrutiny, which in the longer term, will promote better model69
development.70
These questions are routinely addressed in the area of safety engineering, where ensur-71
ing that the correct device has been built, and that the device has been built correctly are72
potentially of critical importance. Consider a simple example, the airplane. One assumes73
there are some basic things to get right when building an airplane, for example the need74
for wings and an engine, but what you build also depends on what the plane is to be75
used for. Is it a transport plane or a passenger plane? Is it to be used for short distance,76
or long distance? Ensuring you get the requirements clear ahead of time is important,77
so understanding the purpose for which the plane is to be used is an essential part of78
that process. Equally important is ensuring that what was required, was built correctly.79
Were the right materials used?, was a rigorous engineering process undertaken?, was the80
plane tested appropriately?, are there instructions on how to use it?, and have you taken81
appropriate steps to identify and address possible sources of risk? Safety is now taken82
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for granted by passengers and we are, rightly, assured that safety is a primary concern83
when building and using aircraft. Often that industry, and others, make use of safety84
cases through the process of GSN to establish an argument for the safety of a system85
[13, 15, 18].86
Whilst developing and using a QSP model is not the same as building an aircraft,87
there are analogies between the processes that leads to the construction and application88
of both. A QSP model might be used as a key decision-making tool in determining dosing89
regimes or within clinical trials [9, 10], which has potential safety critical implications, or90
identify avenues of further (expensive) research that might otherwise be avoided. Whilst91
we might not want to establish a safety case for a model, establishing that a model is92
fit for the intended purpose for which it has been designed has the potential to increase93
confidence, transparency and ultimate usage of such models in pharmacological studies94
[20, 34]. GSN in the context of safety, and now in the context of model development has95
been developed at York, and as yet is not widely used. However, it is through this tutorial96
that it is hoped the wider use of such an approach will be adopted.97
In this paper we provide a methodology that can be used to robustly develop ar-98
gumentation structures that examine the rationale employed at various stages of the99
development of a model. By encompassing all aspects of development, from composition100
through implementation, analysis, and documentation; this approach provides a method-101
ological structure with potential to increase confidence in the application of computational102
models as predictive pharmacological tools. Although we ensure the focus is on the ar-103
gumentation approach, we detail its application in the context of a mathematical model104
of granuloma formation in the liver [3], a inflammatory immune response that occurs in105
response to infection with the parasite Leishmania donovani. We show how exploring106
the rationale behind the development of this simulation and assessing the composition of107
the model after implementation, eases the assessment of simulation-derived predictions in108
the context of the purpose for which this model has been designed: to explore potential109
interventions that could further our understanding of treating this disease.110
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LEISHMANIASIS AND COMPUTATIONAL MOD-111
ELS112
Visceral leishmaniasis is a systemic tropical disease which, in the absence of treatment, is113
usually fatal, with 20,000 - 40,000 deaths annually [8]. A defining feature of the immune114
response to infection with Leishmania donovani parasites is the focal accumulation of115
inflammatory cells within the liver: these aggregations are known as granulomas and pro-116
vide a focus for immune mediated elimination of the parasite. The stages of the immune117
response that follow infection and lead to granuloma formation and eventual parasite clear-118
ance are illustrated in Figure S1. Importantly, the cellular composition of the granuloma119
is dynamic and may comprise monocytes, T cells, and a range of other leukocytes includ-120
ing B, NK, NKT, and dendritic cells in differing numbers and relative proportions [29].121
Achieving an appropriate balance between cells that produce pro-inflammatory Th1-type122
cytokines (e.g.IFN) and regulatory cytokines (e.g. IL-10) is important for stimulating123
macrophages sufficiently to kill intracellular Leishmania, but without causing an over-124
exuberant immune response that leads to destructive tissue pathology [29, 33]. Defining125
how this balance across multiple cell types evolves over time during natural infection and126
and how it might alter as a consequence of the administration of drugs and other therapies127
provides a significant challenge in experimental immunology.128
To generate insight into this important open question and move towards the devel-129
opment of novel therapeutics against Leishmania donovani, experimental techniques are130
required that are both less invasive and more ethically achievable than those used to study131
HVL or EVL. Computational and mathematical approaches permit the development of132
models that do not share the same constraints, and add capacity to interpret underlying133
biological data [22] and to provide an experimental tool for exploring new hypotheses that134
could be examined using traditional experimental approaches [11]. This methodology has135
previously been employed in the development of a Petri net model of granulomatous in-136
flammation in the liver of mice [3], motivated by the need to develop a tool capable of137
generating insight into the importance of macrophage deactivation in immune regulation.138
For the full design, implementation, and analysis detail that underlies this model we re-139
fer the reader to the models accompanying publication and supporting materials [3]. To140
provide a brief overview for the purposes of this tutorial, the Petri net [25] (notation in141
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Figure S2A)) captures biological entities involved in disease progression and resolution (T142
cells, phagocytes, NKT cells, NK cells, and the Leishmania parasites ) as places that hold143
a number of counters. These counters signify the levels of each component at a particular144
time-point of the simulation. Between each place are transitions that move tokens from145
one place to another, decreasing or increasing the number of tokens as required (specified146
by different line and arrow combinations, as shown in Figure S2(A). Each transition is147
designed to capture a biological process, and is a mathematical construct controlled by148
a number of parameters. At each timepoint the transitions between places fire at a rate149
determined by probability density functions and the number of tokens in each place. The150
simulation is designed to capture disease progression and resolution over an extended time151
period. A high level overview of the leishmania Petri net model is reproduced from [3],152
in Figure S2(B).153
By running the Petri net model under different simulated physiological conditions (pa-154
rameter exploration), the authors were able to suggest pathways through which regulation155
of effector functions occur within the granuloma. Yet, for the potential of these insights156
to further our understanding of the disease and impact therapeutic development to be157
realised, it is vital that the composition, implementation, and analysis processes through158
which the model has been developed are transparent and understood.159
ENGINEERING TRANSPARENCY160
In this section we outline a process using structured argumentation that assists the record-161
ing of justifications and rationale for both the biological detail and engineering processes162
that underlie the development of a computational model. The process and associated163
tools to support that process take inspiration from the field of safety-critical systems,164
where it must be demonstrated that a software system is as safe as reasonably practicable165
[17]. Acceptable safety can be established and presented using arguments over evidence.166
For increased accessibility and ease of communication, Goal Structuring Notation (GSN)167
[30, 2] was developed as a visual notation for the presentation of arguments detailing168
safety cases in critical systems engineering. The role of GSN in the wider safety commu-169
nity is significant with various large industries making contributions to the GSN standard170
[1].171
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In exemplifying an approach to expose the rationale underlying the development of172
a model, we utilise, and suggest the use of, a previously published argumentation tool173
by ourselves, Artoo [4], that permits the creation of a diagrammatic summary of the174
structured argument of fitness for purpose. The semantics of the argumentation structure175
employed in Artoo are inspired by that of GSN, with some modifications introduced176
to allow an alteration of focus from safety cases to providing a rationale for fitness for177
purpose. The argument is presented as a tree of connected argument components, of178
specific shapes (Figure 1). The semantics are detailed in Figure S3. These components179
start from a top-level claim (a GSN goal). At the beginning of the process a set of180
fitness-for-purpose requirements (referred to as goals or claims, that the argument seeks181
to substantiate) should be established, with an accompanying set of strategies that can be182
used to assess whether the requirement has been met. The strategies typically break down183
goals into sub-goals, and eventually link to evidence supporting the claim, alongside the184
source of the evidence where appropriate. If a requirement cannot be fully supported by185
available evidence, for example where there are gaps in the biological understanding, then186
the assumptions and abstractions made in place of this evidence are documented, opening187
all implementation decisions to scrutiny by other researchers in the field and identifying188
areas of biological study that have been overlooked or require further laboratory work.189
The process of constructing a claim using the semantics in Artoo is described in Figure190
S5.191
Figure 1: Caption
Arguing Fitness for Purpose192
As outlined above, whereas GSN is applied to demonstrate evidence in safety cases, our193
purpose is to develop a fitness for purpose argument with respect to a model. This change194
in motivation introduces a subtle but important change to the semantics. When arguing195
over safety, it is critical that a claim is terminated by a suitable evidence node supporting196
that claim. However, when documenting our rationale that a model is fit for purpose,197
the construction of an argument may not have a clear ending, in respect of there being198
no available evidence to substantiate a claim [4]. Where this happens, this should not199
automatically be seen as a weakness in the model, yet could instead reveal a number of200
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things. First, that a claim that is believed to be reasonable may in fact not be reasonable201
at all, and the process of constructing the argument has led to this conclusion. At this202
point, it might be wise to review the argument, alongside the model to investigate why203
this might be the case. Second, it might be that the claim is reasonable, but there is no204
evidence that is acceptable (as defined by the creator of the argument structure). In the205
case of arguing fitness for purpose, the claim can be left as undeveloped, that is the claim206
can remain in the argument structure, but highlights a clear gap in the evidence base,207
thus providing informative transparency of the lack of evidence to support the claim.208
Such a modification is vital in QSP modelling applications, where expert opinion and209
assumptions have to be used to mitigate the fact that the understanding of the biological210
system may be incomplete.211
Taking the description in Figure S4 as a template of how to develop a claim, we turn212
attention to developing claims that encompass all stages encountered in model develop-213
ment. In Figure S5 we have split the process into seven distinct phases, all of which,214
we believe, greatly benefit from the adoption of a structured argumentation approach in215
revealing the rationale employed at that stage. To exemplify creation of argumentation216
at each phase, we now go through each in turn, providing case study examples in the217
context of leishmaniasis.218
Step 1 - Define Purpose of the Model219
As can be seen in Figure S5, understanding and defining the intended purpose of a model220
is a key part of the process, as the rationale for the other key phases of model development221
is strongly linked to that purpose. Purpose in this context can be defined as for what222
question the model is intended to answer. This purpose may vary from being a general223
model intended to explore a range of hypotheses and capture many components, or a very224
specific model that is intended for a distinct scientific question. In either case, a clear225
purpose should be defined and a clear scope of the model established, with key questions226
derived that the model will be used to address. The definition of the purpose forms the227
first stage in the construction of the argument structure: the top level claim. As described228
in Figure S3, this top level claim is usually associated with context nodes that define the229
key terms used to specify that purpose. From here, strategies are then set that will be230
used to argue that the top level claim is met: that the tool is fit for its specified purpose.231
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Figure 2 shows the top level of the argumentation structure used to explore the ratio-232
nale underlying the development of the leishmaniasis model. The purpose of the model233
is clearly stated: to explore the effects of the cytokine IL-10 on EVL, parasite infection234
and regulation of granuloma formation. The top level claim is therefore made that the235
model effectively captures EVL in the liver, thus a useful tool for meeting the intended236
purpose. Attached to this claim are six strategies that will be used to support the claim.237
It is hopefully easily noticed that these six claims correspond to the six rounded rectan-238
gles in Figure 3: an examination of the rationale of each phase in the process of model239
development. This section continues with examining each of these sections in turn.240
Figure 2: Caption
Step 2 - Assess available biological evidence241
Once a purpose has been defined, an understanding of the underlying pharmacological242
and biological processes that will be used for the development of the model needs to be243
established. It is often at this stage where the scope of the model can be compromised,244
with the desire to include as much biological information as possible, but possibly at the245
expense of simplicity (or necessity). Clear rationale for what biological and pharmacolog-246
ical evidence is being used should be produced: without a specification of the data used or247
any assumptions employed, it is difficult for researchers using model-derived predictions248
to relate this prediction to their own experimental study. Step 2 of our process supported249
by argumentation is used to assess (i) the scope of any supplied biological data; (ii) the250
understanding gleaned from experts studying the biological system and (iii) the areas251
of understanding that are currently lacking. For each of these, an argumentation claim252
will be established and an appropriate strategy developed to support the claim. This all253
contributes to creating the scope of the model. For example, evidence could exist as a254
log of the experiment that collected the data, or a list of time-points at which the data255
was collected. Employing this technique ensures that the model developer is aware of the256
extent to which the current biological system is understood, and the scope of which any257
data can be included in the developed model.258
Figure 3 expands on the known Biology. At this stage of the process we are document-259
ing what has been considered and collecting evidence for mechanisms and species without260
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making a judgement of whether they will be included in the model - this judgement is261
made in step 3. The strategy considers the cell populations, cytokines and chemokines262
that are mentioned in relevant literature. This is useful for generating a list of species263
that the modeller may later include, or exclude, depending on the weight of evidence264
for their involvement. Also on the top level is the micro-environment, which if correctly265
scoped, may exclude populations or mechanisms that fall outside the intended purpose266
of the model. As an exemplar for the purposes of this tutorial, we have expanded on267
the cytokines, showing a list of all the cytokines that are considered in the literature.268
Although the complete argument expands the rationale for inclusion of all cytokines, our269
exemplar expands on IL-10 and IL-1. For IL-10 it is thought that increasing levels of270
IL-10 are associated with parasite growth and suppresses parasite clearance [37, 19, 28].271
IL-1 is a known pyrogen (meaning that it can cause the host body temperature to rise),272
and can potentially contribute to parasite killing through heatshock [31].273
Figure 3: Caption
Step 3 - Rationale for Biological Assumptions274
In step 2, consideration is given to the scope of the underlying biology and pharmacoki-275
netics, without consideration of how this will be implemented in any model. However,276
that step may also have revealed areas of biological understanding that are incomplete,277
yet need to be included in the model. This can be seen in Figure 4, where the impact of278
the pyrogen IL-1 is noted as not being fully understood. Where such evidence gaps are279
identified, well informed, justified, assumptions will need to be introduced into the model.280
It is critical that the justification for any such assumptions are documented alongside the281
predictions generated by the model, as their introduction may have an influence on the282
validity of that prediction. If, for example, the purpose of the model is to produce pre-283
dictions that inform laboratory research, it is vital that confidence in the assumptions are284
a fair reflection of the experimental system on which they will be testing this prediction:285
key when financial and technical resources have to be considered within a study.286
In Figure 4 we expand on two examples from the cytokines that were being considered287
in Step 2. We demonstrate two common simplifying assumptions. For IL-1, the proposed288
mechanism of action on parasite load is killing of parasites indirectly via heat shock. It289
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can be argued that heat shock is neither necessary nor sufficient for parasite clearance,290
as evidenced by the lack of impact of IL-1 receptor blockade on acquired resistance or291
granuloma formation[33]. Considering the purpose of the model, it is reasonable to assume292
that IL-1 can be excluded despite the fact that there is some evidence that it could impact293
parasite load. This exclusion of IL-1 is one type of simplifying assumption. Figure 6294
also shows a partially developed argument for merging IFN and TNF which ends in the295
undeveloped claim that they perform the same function and can be merged into a single296
proxy species. Both of these simplifying assumptions depend on the stated purpose of297
the model for their potential validity. Both simplifying assumptions are to some extent298
judgement calls that multiple stakeholders may wish to examine and influence, which299
elucidates the importance of transparency and documentation of the argumentation.300
Figure 4: Caption
Step 4 - Rationale for Modelling Approach301
In implementing any model of a biological system, there may be several techniques that302
could be selected (i.e. modelling paradigms, software tools). In this step, the model303
developer can use argumentation to justify the engineering decisions taken during model304
implementation. There can be a temptation to choose the modelling tool of convenience,305
one that a modeller is familiar with, however, this can be a mistake. It is well known306
that different modelling techniques can show different types of results and have an effect307
on what is observed [14]. Therefore, it is important that the rationale for the choice of308
modelling system be exposed. As an example, a claim could be made that an agent-based309
modelling paradigm is most suitable for addressing the question of concern. Strategies310
would then be employed to determine whether this is indeed the case, or whether other311
approaches such as Ordinary Differential Equation (ODE) modelling would be more ap-312
propriate. By using argumentation at this stage, the developer has a record of the im-313
plementation decisions that were taken, with a fully evidenced justification of why these314
decisions were taken.315
Figure 5 shows a subsection of the argument concerning the modelling approach316
adopted in the development of the Leishmaniasis simulation. From the top claim specified317
in Figure 2, the strategy is to argue the appropriateness of the adopted approach, in this318
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case stochastic Petri nets. From here, our claim is that the adopted paradigm provides319
the means to represent the required aspects of the biological system. To support this320
claim, one would be required to compare the available approaches, and as such the stated321
strategies involve examining implementing the model as a Petri net, agent-based model,322
or ODEs. For the scope of this tutorial, Figure 5 expands on the Petri net suitability323
claim, arguing that we can capture the required stochasticity, capture granuloma hetero-324
geneity, handle small integer number calculation, and produce an implementation that is325
computationally tractable. In this case we are able to evidence all four claims, suggesting326
we have a suitable approach for capturing the key aspects specified in the claim.327
Figure 5: Caption
Step 5 - Rationale for Modelling Assumptions328
By employing steps 2 and 3, any gaps in the biological understanding became apparent and329
were addressed via appropriately justified and documented assumptions. Previously we330
described how critical these assumptions were when relating the simulated system to the331
real system of interest. Additionally, this critical issue is also applicable when introducing332
simplifications that may be made during the development of the model. At this stage, it333
may be sensible to determine whether the full extent of the biological system of interest334
scoped in step 2 needs to be captured in the model. For example, modelling the impact of335
a number of cell receptors and their respective chemokines could potentially be reduced336
to a model of a single proxy chemokine and receptor pair, if what is being examined is337
the higher-level effect produced by these chemokines and receptors as an ensemble. An338
example of a similar issue could be a biological system consisting of tens of thousands of339
cells: complexity that may not be tractable to simulate. The simulation developer may340
determine that only capturing a percentage of that environment is enough to understand341
the overall emergent behaviour of that system. Taking a number of biological concepts342
and simplifying these into a single mechanism, or determining a biological concept to be343
unnecessary given the scope of the model, does however introduce assumptions that must344
both be taken into consideration when relating a model-derived result to the real system345
and be justified.346
Figure 6 shows a subset of the argumentation structure produced from the top level347
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strategy to argue over the modelling abstractions. Similarly to previous examinations of348
the biological information and assumptions, here, claims are made concerning the appro-349
priate capture of the cells, cytokines, chemokines, and the environment. For the scope of350
this tutorial, we have included the argument of one key assumption in the model: that351
the dynamics of monocyte derived macrophages, dendritic cells, and neutrophils can be352
adequately captured by a single cell type. Such an assumption reduces the complexity of353
the model, yet could impact the meaning of any results generated. As such we support354
this simplification with two claims: that parasites are not observed to replicate in these355
cell types, yet these cells contribute to the cytokine microenvironment in the granuloma.356
The first, supported by collaborators opinion, would suggest that these cells could po-357
tentially be abstracted out of the model altogether, as they do not influence the models358
purpose. However this is contradicted by the second, which makes the claim that these359
cells contribute to the cytokine environment of interest. As such, we argue that these are360
required, but can be abstracted to a single proxy cell type that expresses the cytokines361
identified in Figure 3.362
Figure 6: Caption
Step 6 - Engineering the Implementation363
When going through this process alongside the development of a simulation, the developer364
will now have justified the modelling approaches they are going to use (step 4) and the365
abstractions they will make in implementation (step 5). The next step is to implement366
the model. Issues of trust in simulations for science have previously been raised, and367
much has been written on how this could be countered by the release of code [27, 26, 24].368
However, we believe our approach to structured argumentation also provides a means of369
increasing trust in the implementation alongside such arguments. Argumentation could,370
for example, be used to argue that the code meets the specifications developed in the371
previous phases above, and that an adequate testing routine has been developed and372
performed.373
Figure 7 shows a subset of such an argumentation structure for the Leishmaniasis374
simulation, arguing that the system meets requirements for implementation and has been375
adequately tested. The former is in some respects easier to show: claims can be made376
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concerning particular biological behaviours that are evidenced by aspects of the model377
(such as equations), and links can be drawn to evidence derived on argumentation dia-378
grams from previous phases of the process. Testing a complex simulation is much more379
difficult. In Figure 7, the strategy to argue that the Leishmaniasis simulation was ade-380
quately tested has been to ensure adequate structural coverage of the code by tests. In381
this case, as is typically the case in high integrity software engineering, this strategy is382
split into three phases: requirements testing [36]; unit testing [23]; and manual review.383
Requirements testing ensures that the system has a collection of requirements describ-384
ing the tasks that the system should perform, and it ensures that each requirement has an385
associated test (or collection of tests) that demonstrates the system fulfilling the require-386
ment. The requirements tests are run through the implementation to check that they pass387
and to measure their structural code coverage. If all the requirements tests pass, then388
this demonstrates that the implementation performs its tasks correctly. If all the require-389
ments have appropriate tests that pass, then this demonstrates that the implementation390
performs the correct tasks. If the requirements tests produce full code coverage, then this391
demonstrates that the implementation performs only its tasks and nothing else.392
In practice, it might be impractical to achieve full code coverage using just require-393
ments tests at the system level. For example: there might be some error-checking code394
deep within the call tree that is difficult to trigger under normal conditions. For these395
cases, unit tests are used to inject particular values into the implementation to increase396
the code coverage of the requirements tests.397
Even using unit tests, it may not be possible to achieve full code coverage for some398
types of code. For example: robustness checks, system libraries, or code that only executes399
when running the system in a different mode. For these cases, the code is reviewed400
manually to either determine that it will not execute in the situations we are providing,401
or to argue why it does not need to be tested (for example, a commonly used system402
library). Given the criticality of models we consider adequate testing to mean achieving403
90% statement coverage and 90% branch coverage through requirements tests and unit404
tests, with the remaining code reviewed manually.405
Figure 7: Caption
14
Step 7 - Justify experimental approach / analysis406
Once a simulation has been designed and implemented, model developers will perform407
in silico experimentation and statistical analyses designed to elucidate biological insight408
from the model [6]. However, for full transparency, the model developer should adopt an409
argumentation approach to argue that the experiment is necessary and designed correctly,410
prior to any simulation runs being performed. This will ensure that the time spent on411
running complex simulations is minimised, and also ensure the analysis routines take into412
account implementation inherent issues such as the inclusion of stochastic behaviours.413
Results from the experiments and the analysis techniques employed to fully understand414
the behaviour of a model need to be interpreted in terms of (i) the scope of the designed415
simulation; (ii) the biological system being studied. The final stage of our process uses416
evidence-based argumentation to draw conclusions from simulation-derived results, util-417
ising the evidence compiled in Steps 1-5. Here, the simulation developer may make a418
claim regarding some insight generated during the modelling project. They may then419
draw on evidence from the complete argumentation process to show that the generated420
insight can be supported. Figure 10 shows a subset of the argument that the experimen-421
tal analyses performed are well designed and appropriate. This is divided into sub-claims422
that describe two sets of experiments: (i) statistical analyses employed to understand the423
behaviour of the model, and (ii) in silico experimentation used to perform experiments424
that may be difficult to perform in the laboratory. Both sets of experiments are detailed425
in [3]. Figure 8 shows one of each: appropriate sensitivity analyses for the first and IL-10426
related experimentation for the second. In both cases the claims are supported by the427
reasoning for the particular experiment, the experimental strategy, and the results. By428
ensuring the design of such analyses is transparent, others using the result in their own429
context are clear as to how each prediction has been derived.430
Figure 8: Caption
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USING ARGUMENTATION TO REFINE MODEL431
PURPOSE, DESIGN and IMPLEMENTATION432
Where the described process is employed, the key biological information to be modelled433
will be identified, translated into a format that can be encapsulated within a computer434
code, and developed into a computational model through which predictive experimenta-435
tion can be performed. Completing a process where each step on this path is justified and436
documented is advantageous in determining the degree to which predictions made can be437
related to the real-world system being studied [4]. Whereas the process described above438
focuses on that process of exploring the rationale of a model either during construction439
or retrospectively, a completed argumentation structure should however not be seen as a440
static document, and offers further advantages in cases where a model is to be repurposed441
or refined.442
As an example, consider the Leishmaniasis simulation that has been used as a case443
study throughout this tutorial. This model captures the processes within EVL, an ex-444
perimental mouse model of visceral leishmaniasis. However, the overriding objective is to445
further our understanding of Leishmania in order to expedite the development of novel446
therapeutics against the disease in humans. Although it is generally accepted that the447
mouse provides an adequate model for exploring the disease in humans, this remains a448
model of the disease in the mouse, and the links between this model and the human disease449
need to be understood. One potential strategy could be to repurpose the model: altering450
the focus to capture HVL rather than EVL. If this were to be undertaken, possessing a451
rationale for the design, construction, and analysis of the computational model of EVL452
would be very useful in determining the extent to which the model needs to be altered453
to capture HVL. For example, an assessment of the biological information on which the454
EVL model was constructed (step 2) and the assumptions that were introduced in that455
model (step 3) would determine the relevance of that data to any model of HVL. Where456
argumentation was used to construct the original model, we also argue that the approach457
could be very useful in arguing over any alterations that are made if the purpose of the458
model is adjusted.459
Additionally, possessing a complete rationale detailing model development and analy-460
sis could be advantageous in assessing the composition of the resultant model. Following461
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a detailed exploration of the biological information, addition of necessary engineering462
assumptions and abstractions, and implementation of the computational tool, the Leish-463
mania Petri net model comprised 174 transitions between places, with each transition464
designed to capture a particular biological pathway. Although the authors were able to465
show that the model could recapitulate the progression of the disease, in comparison466
to a laboratory experimental model, and predict cellular composition within granulomas467
[3], no analysis has been previously undertaken as to the necessity of each of the 174468
transitions in the model. Such an analysis has the potential to infer further information469
regarding the key biological pathways involved in disease progression and immune system470
regulation. From an engineering perspective, the most computationally intensive process471
in running a Petri net model is initialising each of the transitions: if a number of these472
transitions were found to be unnecessary, there is thus potential for a large increase in473
simulation performance.474
To examine the impact of each of the 174 transitions, we modified the Petri net model475
such that the simulation recorded the number of times each transition fired. As the476
firing of a transition is potentially dependent on the initial conditions and parameter477
values, we ran the model under a number of initial conditions, over the parameter ranges478
originally explored by [3]. To ensure adequate coverage of the parameter space, we utilised479
the ASPASIA sensitivity analysis toolkit [16] to generate 600 sets of parameter value480
combinations using latin-hypercube sampling [32, 35]. By executing the Petri-Net model481
under each of the 600 conditions, we were able to determine the number of times each482
transition fired across the parameter space. Where a transition was found not to fire for483
any set of initial conditions, one could question the necessity of including this pathway in484
the model.485
This analysis identified 47 of the 174 transitions between Petri net places that were486
never fired (28%), suggesting a number of the transitions could potentially be removed.487
Although this would reduce the computational complexity of the model, making simulated488
analyses and experiments faster, it is important that we understand the impact this489
change has in terms of our understanding of what the model captures. The argumentation490
constructed in the development or analysis of a model provides a tool through which any491
impact can be assessed. Of these 47 transitions that are related to T-Cells, NKT, and NK492
cells, the majority of non-firing transitions are found to control the silencing of cells due493
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to a lack of a certain cytokine and reprise of cytokine production due to an increase in494
environmental cytokine levels. This would suggest that the simulation is never reaching495
thresholds where these cells are transitioning states. Knowing this, it becomes possible to496
read through the argumentation to determine if this cell behaviour could emerge from the497
manner in which the model has been constructed, or whether this is an error. This result498
could also assist conversations with collaborating biologists, and provide insight into the499
composition of the granuloma environment.500
DISCUSSION501
Technological advancements and a focus on interdisciplinarity has resulted in an increased502
prevalence of laboratory studies being paired with computational modelling research,503
motivated by the potential to reduce animal experimentation, reduce costs, and perform504
experimentation that is not possible in the laboratory or informs future clinical studies.505
However, for computational modelling studies to achieve that potential, it is critical that506
the relationship between the model and the biological system being captured is fully507
understood. Any researcher would need to have a high level of confidence in a model-508
derived prediction before seeking to invest time, expertise, and financial resources into509
investigating that prediction further in the real system.510
The notion of increasing confidence in the application of computational models in511
biological research is not new however, yet has tended to focus on the end result: the512
implementation [27]. Such focus has led the field to suggest open-source code [26], that is513
potentially checked by third-parties [24], and included alongside publications describing514
that model [12]. However, the issue of confidence in a model must go further than that:515
the code may well be adequate to do the job it has been designed to do, this does not516
imply that the biological system has been captured appropriately [5].517
In this tutorial we have detailed a process through which the rationale underlying518
the design, implementation, and analysis of a model of a biological system is generated.519
We see this process being applied either within a process of model construction or as520
a tool through which an assessment of a previously developed model can be performed.521
This process begins by examining the purpose of the study: what it is that the model522
will be used for. This establishes the scope prior to any experimental work, to ensure523
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the tool is not being used to generate predictions for which it has not been designed.524
This purpose is then a key consideration in an examination of each component phase525
of model development: assessing the biological data; making necessary assumptions in526
place of a lack of information; choosing the correct modelling paradigm; introducing527
necessary modelling assumptions; engineering the computational model, and performing528
experimentation using the tool. Any omissions or ambiguities inherent in any of these529
phases could impact the potential to relate a model prediction to the real-world: for this530
to be detected, all design decisions must be transparent.531
Adverse outcome pathway (AOP) tools have found application in toxicology and in532
studies of human risk assessment, providing a means to specify how interactions at the533
molecular, cellular and organ level can be linked to an adverse outcome [38]. Presented534
as a flow diagram, AOPs can show the strength of evidence supporting the events in535
the outcome pathway, yet have come under criticism for splitting the representation of536
the process from the evidence, providing a simplistic representation of the toxicological537
process [38]. More generally, yet applicable to QSP-related models, the ODD (Overview,538
Design concepts, Details) protocol does permit the specification of the purpose behind539
the creation of a model, the inclusion of biological components, and modules describing540
the implementation of biological behaviour, alongside relevant assumptions [21]. The541
focus of ODD is scientific repeatability, rather than fitness for purpose as specified in this542
tutorial, and lacks the recording of model experimentation and statistical analyses, and543
motivation for performing those experiments [21]. In producing this tutorial we are not544
hoping to replace either technique: argumentation could be used alongside either, but545
we do contend that neither method provides the complete set of information required to546
convince researchers that a model is appropriately constructed and analysed to meet its547
intended purpose.548
We believe that arguing over the rationale for each of the model development phases549
identified in Figure 3 can provide a transparent evidence base upon which the contribution550
of a computational model can be assessed. Alongside a description of the process involved551
in examining the rationale at each phase, we have shown an example application of the552
process in examining the rationale underlying the development of a model of Leishmani-553
asis: developed to further understand this neglected tropical disease to generate insights554
that could inform future therapeutic studies [3]. In addition to exposing the rationale555
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behind this model, we then described how this argument could potentially be used to de-556
termine the links between this model and human visceral leishmaniasis (HVL), and how557
the argument could be useful in examining the composition of the model with respect to558
computational complexity. The approach offers more than a process to be employed in559
model development or assessment, and is advantageous in redefining the purpose of, or560
refining the composition of, models developed for QSP studies. Where a computational561
model is closely tied to a mouse study, structured argumentation using the approach de-562
tailed in this tutorial has the potential to provide a robust way of understanding how the563
model could be repurposed for human studies that predate or inform clinical trials.564
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Figure 1: Description of the notation used in the creation of an argument.
To show how these components are linked together, we present the
description of each component within the format of an argument structure.
25
Figure 2: Top level
argument in the process of arguing that the leishmaniasis simulation is fit for
purpose. Black diamonds indicate the strategies in this figure are expanded
upon below.
26
Figure 3: Arguing appropriateness of evidence used as a basis forthe
Leishmaniasis Simulation in [3].
27
Figure 4: Argument that the biological abstractions introduced in the model
are suitable. In this case, the approach is exemplified by focusing on
abstractions of cell type to be included in the model.
28
Figure 5: Argument that the adopted modelling approach is adequate given
the research context. In this case, the approach is exemplified by focusing on
the choice of modelling paradigm: Petri Net, Agent-Based model, or ODEs.
29
Figure 6: Subset of the argument that supports the rationale for abstracting
modelling abstractions.
30
Figure 7: Subset of the argumentation structure used to argue that the
implementation of the model is adequate for meeting the purpose specified
in Figure 2.
31
Figure 8: Subset of the argumentation structure for the design of the
experimental analysis.
32
Figure S1: Summary of immune response associated with granuloma formation in leish-
maniasis. A. Within hours of experimental infection with Leishmania donovani, dendritic
cells present parasite antigens to nave T lymphocytes in lymphoid tissues to initiate an
adaptive immune response. B. Simultaneously, parasites in the liver infect resident liver
macrophages (Kupffer cells), stimulating the production of chemokines that attracts in-
nate lymphoid cells (of which NKT cells are best characterized). NKT cells engage with
infected Kupffer cells via cognate receptor-ligand interactions, amplifying the chemokine
response to attract additional Kupffer cells, NKT cells and eventually other cell types (see
D, below). C. Over the first few days of infection, T cells differentiate into a variety of
subsets (Th1, Th2, Treg), producing cytokines that may cross-inhibit or cross-stimulate
T cell differentiation. These cytokines also promote (e.g. IFN) or inhibit (e.g. IL-10)
the ability of macrophages to kill Leishmania. D. The relative balance of different T cell
subsets, together with monocytes, dendritic cells, and occasionally neutrophils that are
attracted to the expanding granuloma determines parasite burden. Notably, granuloma
development is asynchronous (lower right). E. Reduction in parasite burden is achieved
when Th1-type immune responses become dominant. F. Resolution of infection is ac-
companied by granuloma involution (loss of cellularity) and a restoration of homeostasis.
Experimental and modeling data suggest, however, that some residual parasites survive
in some granulomas due to regulatory mechanisms.
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Transition (T1&T2)
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Figure S2: Petri-Net modeling approach used to develop the case study model of gran-
uloma formation in Leishmaniasis. A: Schematic of Petri net Places (P1,2,3,4), tokens
(black circles in places) and transitions (T1,2). Continuous line, Standard arrowhead:
takes tokens from the input places and moves tokens to the output place. Dotted Line,
Standard arrowhead: The number of tokens of a place is used in the evaluation of the
rate of a transition. Continuous line, Full circle: Target transition only performed if the
appropriate number of tokens is present in input. Continuous line, Empty circle: Disables
the target transition if the appropriate number of tokens is present in the input place. B:
High level Petri-Net model of granuloma formation, reproduced from [3].34
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Semantics Used in Artoo Argumentation Tool
A Claim is an identified fitness-for-purpose requirement that 
the argument is seeking to substantiate, if possible. As an 
argument around a claim is constructed, that argument can 
be broken down into subsets of claims that, if substantiated, 
support the substantiation of the higher level claim
Context
Assumption
Strategy
Evidence
Strategy
A Strategy node should state the specific actions that have 
been taken to substantiate the claim to which this node is 
attached. This strategy may consist of breaking the claim 
down into a subset of claims which are then argued in turn.
Context
A Context node should be used to provide contextual 
information concerning information in a node to which it is 
attached. This information may be definition of particular 
words or phrases (such as adequate) or the level at which 
the attached claim is deemed to have been substantiated.
Sub-Claim
Unsubstantiated 
      Claim
Claim Continued
Context
Assumption
Justification
A
Assumption
An Assumption node provides a means of specifying any 
information that is assumed to be true when arguing over a 
claim or designing a strategy to examine a particular claim. 
Explicitly stating the inherent assumptions eases the process 
by which others can assess the extent to which the 
argument over a particular claim holds.
J
Justification
A Justification node should contain the reasoning for the 
application of a particular strategy in order to substantiate a 
claim. Justifying the approach used explicitly can reveal the 
extent to which alternative strategies have been considered, 
and why this strategy was selected over those alternatives.  
Unsubstantiated
Claim
Unlike the application of structured notation in formal safety-
case arguments, a claim can be shown to be 
unsubstantiated in the approach described in this paper. 
Biological systems are not fully understood, and it may not 
be possible to generate evidence to substantiate the 
complete set of fitness for purpose requirements. Where this 
is the case, it is critical that the lack of evidence is explicitly 
stated in the argument, and the limitations of the model are 
shown. In our approach, a lack of substantiating evidence is 
shown by attaching a white diamond to that claim
As the argument becomes more complex, it may become 
difficult to follow. As such we have introduced a black 
diamond notation, representing the continuation of the 
argument surrounding this claim on a different diagram
Node containing the Evidence that is used to substantiate an 
attached claim. In Artoo, it is possible to hyperlink to this 
evidence, which could include publications, experimental 
results, statistical analyses, etc. 
Claim
Continued
Evidence
DefinitionNotation Description
In Context Of
Supported By
Connected To
Figure S3: Semantics of diagram language used in Artoo
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Identify a claim that the argument seeks to support. This is represented within a rectangle. The objective 
is to detail how this claim can be supported with available evidence, if possible.   
Each claim is usually examined within a given context. This may 
involve defining the meaning of key terms stated in the claim. For
example, if the purpose of the model was to adequately capture
a biological system, adequate must be defined. Any context 
definitions are given in rounded rectangles
A
B
C
D
E
Box 1: Developing a Claim
Each claim is accompanied by one or more strategies that will be
used to determine if that claim can be supported. This could, as
examples, be a particular experimental strategy or systematic 
literature review. A strategy is always stated in a parallelogram.
A claim or strategy can also be accompanied by a justification or
assumption node to provide more detail on the choice of the claim
being made or the strategy that was followed. Semantics in 
Supplementary Figure 1 
Strategies, unless leading to evidence (see part E), are then
broken down into sub-claims, and the process repeated. In this
case, the strategy is divided into four sub-claims, each of which
examines a key part of the model development process.
If evidence can be provided that supports a claim, this is 
stated in an evidence node: a circle. In Artoo, electronic 
links to this evidence can be provided. 
Diamonds on the diagram indicate either:
(i) a claim cannot be supported. If no evidence can be 
provided, a white diamond can be used to show this is 
the case.
(ii) the argument is detailed on another diagram. A black
diamond is used to show the claim is fully described
elsewhere.
Figure S4: Process of developing a specific claim, using the diagrammatic notation used
in Artoo.
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2. Assess 
Biological
Evidence
3. Rationale for
Biological
Assumptions 4. Rationale for
Modelling
Approach
5. Rationale for
Modelling
Abstractions6. Engineering 
 & Testing the 
Implementation
7. Rationale for
Experimental
Approach &
Analysis
Figure S5: Process through which assessing the rationale for model design, implemen-
tation, and analysis should be conducted. Each stage of the process is grounded in the
purpose for which the model was developed. Arrows linking to Purpose are bidirectional
as the purpose shapes what assumptions and abstractions are appropriate, and conversely,
decisions about assumptions and abstractions that are made can de facto alter the pur-
pose for which the model is fit. Note the lack of defined end point: arguing fitness for
purpose has potential to inform later iterations of model and study development.
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